Quantinno Capital Management
NBIX icon

Quantinno Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Quantinno Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$12.9M Buy
91,189
+11,534
+14% +$1.85M 0.01% 979
2026
Q2 		$13.4M Buy
79,655
+10,156
+15% +$1.51M 0.02% 867
2026
Q1 		$9.16M Buy
69,499
+42,508
+157% +$5.64M 0.02% 905
2025
Q4 		$3.83M Buy
26,991
+10,786
+67% +$1.56M 0.01% 1121
2025
Q3 		$2.27M Buy
16,205
+3,358
+26% +$455K 0.01% 1184
2025
Q2 		$1.61M Buy
12,847
+2,240
+21% +$257K 0.01% 1156
2025
Q1 		$1.17M Buy
10,607
+6,644
+168% +$842K 0.01% 1109
2024
Q4 		$541K Buy
3,963
+1,724
+77% +$213K 0.01% 1211
2024
Q3 		$258K Buy
2,239
+448
+25% +$61.4K ﹤0.01% 1313
2024
Q2 		$247K Buy
1,791
+154
+9% +$21.1K ﹤0.01% 1212
2024
Q1 		$226K Buy
+1,637
New +$224K ﹤0.01% 1156

Other funds holding NBIX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $187B AUM 13.73% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $102B AUM 35.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Quantinno Capital Management's NBIX Position: Q3 2026 in Review

Quantinno Capital Management increased its Neurocrine Biosciences (NBIX) stake by 14% in Q3 2026, buying an estimated $1.85M and bringing the position to 91,189 shares worth $12.9M. The position accounts for 0.01% of the portfolio, ranked #979.

Quantinno Capital Management first reported a position in NBIX in Q1 2024 and has held it in 11 quarters since. The position peaked at $13.4M in Q2 2026. 630 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Quantinno Capital Management held 91,189 shares of Neurocrine Biosciences worth $12.9M as of Q3 2026.
  • Quantinno Capital Management bought 11,534 Neurocrine Biosciences shares in Q3 2026, an estimated $1.85M.
  • Neurocrine Biosciences made up 0.01% of Quantinno Capital Management's portfolio in Q3 2026, its #979 holding.
  • Quantinno Capital Management first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 11 quarters since.
  • Quantinno Capital Management's Neurocrine Biosciences position peaked at $13.4M in Q2 2026.
  • 630 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Quantinno Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.